Literature DB >> 10838067

Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia.

L Flyckt1, J Borg, K Borg, T Ansved, G Edman, L Bjerkenstedt, F A Wiesel.   

Abstract

BACKGROUND: In a previous study of motor unit properties in patients with schizophrenia, muscle fiber histologic and electrophysiologic abnormalities were observed. The present study was designed to compare patients with schizophrenia with healthy control subjects with regard to muscle fiber histology and motor unit function. A second objective was to relate these variables to clinical characteristics.
METHODS: Twelve patients with first-episode schizophrenia and fifteen patients with chronic schizophrenia (DSM-III-R) and 27 matched control subjects were included in the study. Muscle biopsies were performed either in m. tibialis anterior or m. vastus lateralis. Electromyographic recordings (macro EMG) were made from the m. tibialis anterior motor units. Psychiatric ratings included the PANSS and extrapyramidal side effects.
RESULTS: Seven of the muscle biopsy specimens from the patients and one from the control subjects were classified as abnormal (p =.049). The most frequent abnormality was atrophic muscle fibers. Eight patients and no control subjects exhibited pathological macro EMG (p =.032). The findings were present in chronic as well as in first-episode patients with schizophrenia.
CONCLUSIONS: In approximately 50% of the patients, neuromuscular abnormalities were found either in the muscle biopsy or the macro EMG investigations. The results indicate that either a common pathologic process or different pathological processes are at hand in the neuromuscular system in patients with schizophrenia. The findings are compatible with a disturbed cell membrane function.

Entities:  

Mesh:

Year:  2000        PMID: 10838067     DOI: 10.1016/s0006-3223(99)00295-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents.

Authors:  Kazuhiro Suzuki; Syudo Yamasaki; Mitsuhiro Miyashita; Shuntaro Ando; Kazuya Toriumi; Akane Yoshikawa; Miharu Nakanishi; Yuko Morimoto; Sho Kanata; Shinya Fujikawa; Kaori Endo; Shinsuke Koike; Satoshi Usami; Masanari Itokawa; Shinsuke Washizuka; Mariko Hiraiwa-Hasegawa; Herbert Y Meltzer; Kiyoto Kasai; Atsushi Nishida; Makoto Arai
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-27

2.  Nonlinear parameters of surface EMG in schizophrenia patients depend on kind of antipsychotic therapy.

Authors:  Alexander Yu Meigal; German G Miroshnichenko; Anna P Kuzmina; Saara M Rissanen; Stefanos D Georgiadis; Pasi A Karjalainen
Journal:  Front Physiol       Date:  2015-07-10       Impact factor: 4.566

3.  Paradox of schizophrenia genetics: is a paradigm shift occurring?

Authors:  Nagafumi Doi; Yoko Hoshi; Masanari Itokawa; Takeo Yoshikawa; Tomoe Ichikawa; Makoto Arai; Chie Usui; Hirokazu Tachikawa
Journal:  Behav Brain Funct       Date:  2012-05-31       Impact factor: 3.759

Review 4.  From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism.

Authors:  Rolando I Castillo; Leonel E Rojo; Marcela Henriquez-Henriquez; Hernán Silva; Alejandro Maturana; María J Villar; Manuel Fuentes; Pablo A Gaspar
Journal:  Front Neurosci       Date:  2016-11-08       Impact factor: 4.677

5.  An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study.

Authors:  Davy Vancampfort; Michel Probst; Amber De Herdt; Rui Manuel Nunes Corredeira; Attilio Carraro; Dirk De Wachter; Marc De Hert
Journal:  BMC Psychiatry       Date:  2013-01-03       Impact factor: 3.630

6.  A comparative genomic study in schizophrenic and in bipolar disorder patients, based on microarray expression profiling meta-analysis.

Authors:  Marianthi Logotheti; Olga Papadodima; Nikolaos Venizelos; Aristotelis Chatziioannou; Fragiskos Kolisis
Journal:  ScientificWorldJournal       Date:  2013-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.